Comment

Chime Biologics Announced the Completion of $190 Million Series A+ Financing to Accelerate Capacity Expansion

Chime Biologics announced today that it has secured a total commitment of $190 million Series A+ investment from institutional investors in which over $100 million investment has already been closed today. This round financing was led by VMS Group and followed by Fidelity International and Panacea Venture. Earlier in February 2020 Chime Biologics has just completed its Series A financing of $125 million.

Comment

Comment

JHL Biotech Focuses on CDMO and Biologics Development for Global Markets After Spinoff

JHL Biotech has made a strategic decision benefitting all of its patients, shareholders, employees and the company to restructure JHL Biologics and spinoff its China Facility to have a stronger presence in China, with new and additional investment opportunities. With the separation, Chime Biologics (a BVI Company, which is the corporate office of XiKang Wuhan) will have one of the largest and most thorough CDMO capabilities in China Biologics Market. Chime will continue to provide services to clients and business partners from early to late-stage commercial development and manufacturing.

Comment

Comment

CredSimple Acquires Glenridge Health to Build the Industry's Most Comprehensive End-to-End Provider Network Management Solution

CredSimple, the leading cloud-based healthcare credential verification organization, today announced the acquisition of Glenridge Health, a premier technology-enabled provider network management solutions company. This acquisition strategically expands CredSimple's capabilities to include comprehensive provider network development and management services. It also marks a critical investment towards offering CredSimple customers a more vertically integrated and streamlined solution that will allow them to efficiently analyze, build, and manage their networks, while mitigating the burden of provider credentialing through automation.

Comment

Comment

JHL Focusing on New Biosimilar Pipeline and Global Expansion of CDMO Business

JHL remains well-positioned to capture growing market opportunities and implement our long-term strategic plan for sustainable growth, including focusing on executing the rollout of our biosimilar pipeline and the global expansion of our CDMO business. This plan will create long-term value for our shareholders, bolster our strong financial position, and capitalize on the market’s continued optimism in our business.

Comment

Comment

FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

ADMA Biologics, Inc. (NASDAQ: ADMA) announces that the U.S. Food and Drug Administration (“FDA”) has approved ASCENIV™, Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred to as RI-002.  ASCENIV™ is an Intravenous Immune Globulin (“IVIG”) drug product for the treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in adults and adolescents (12 to 17 years of age).  The Company anticipates having the product available for commercial launch during the second half of 2019.

Comment

Comment

Quest Analytics Acquires BetterDoctor

Quest Analytics, the leading provider of network access and adequacy services to health plans and insurance regulatory agencies, today announced that it has acquired BetterDoctor, the nation’s most accurate provider data management platform. Together, the companies will provide the first comprehensive platform that enables health plans to optimize their member experience while complying with federal and state regulations for network adequacy and accuracy.

Comment

Comment

Celgene Corporation to Acquire Juno Therapeutics

Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares). The transaction was approved by the boards of directors of both companies.

Comment

Comment

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion.

Comment

Comment

Scientific Publication by a Group Including Juno Therapeutics Scientific Co-Founder Michel Sadelain Is Featured in Endpoints News Article

CAR-Ts won’t be on the market before next year, but the technology arms race inspired by the prospect of a multibillion-dollar market has inspired a group of prominent investigators to design a new, 3.0 model in the lab that includes a built-in checkpoint mechanism. And it worked like a charm in mouse models of solid tumors - a critical hurdle that the key players have been struggling to clear.

Comment